Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

Experimental & Molecular Medicine, Published online: 16 April 2024; doi:10.1038/s12276-024-01210-5Cancer treatment often uses specific drugs, but sometimes the body can resist these, causing the cancer to return. A study led by Yonsei University College of Medicine researchers looked at the role of a protein, yes-associated protein (YAP), in this drug resistance. They found that another protein, MAP3K3, helps keep YAP stable, which then helps the body resist cancer drugs. By stopping MAP3K3, the researchers could lower YAP levels and overcome drug resistance in breast cancer and skin cancer cells. This suggests that focusing on MAP3K3 could be a good way to treat cancers that resist drugs. The study also shows how important it is to understand how proteins in cancer cells interact.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Source: Experimental and Molecular Medicine - Category: Molecular Biology Authors: Source Type: research